A Phase 2 Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)
Latest Information Update: 23 May 2025
At a glance
- Drugs Hyaluronidase/Pembrolizumab (Primary)
- Indications Diffuse large B cell lymphoma; Hodgkin's disease
- Focus Pharmacokinetics; Therapeutic Use
- Sponsors Merck Sharp & Dohme
Most Recent Events
- 08 Oct 2024 Planned initiation date changed from 29 Aug 2024 to 10 Oct 2024.
- 20 Aug 2024 Planned initiation date changed (estimated date of first participant enrollement) from 15 Aug 2024 to 29 Aug 2024.
- 20 Aug 2024 Status changed from not yet recruiting to recruiting.